P-glycoprotein (Pgp; mouse MDR3) was expressed inPichia pastoris, grown in fermentor culture, and purified. The final pure product is of high specific ATPase activity and is soluble at low detergent concentration. 120 g of cells yielded 6 mg of pure Pgp; >4 kg of cells were obtained from a single fermentor run. Properties of the pure protein were similar to those of previous preparations, except there was significant ATPase activity in absence of added lipid. Mutant mouse MDR3 Pglycoproteins were purified by the same procedure after growth of cells in flask culture, with similar yields and purity. This procedure should open up new avenues of structural, biophysical, and biochemical studies of Pgp. Equilibrium nucleotide-binding parameters of wildtype mouse MDR3 Pgp were studied using 2-(3)-O-(2,4,6-trinitrophenyl)adenosine tri-and diphosphate. Both analogs were found to bind with K d in the low micromolar range, to a single class of site, with no evidence of cooperativity. ATP displacement of the analogs was seen. Similar binding was seen with K429R/K1072R and D551N/D1196N mutant mouse MDR3 Pgp, showing that these Walker A and B mutations had no significant effect on affinity or stoichiometry of nucleotide binding. These residues, known to be critical for catalysis, are concluded to be involved primarily in stabilization of the catalytic transition state in Pgp.
P-glycoprotein (Pgp)1 is a plasma membrane-located, ATPdriven drug efflux pump that confers multidrug resistance on mammalian cells (1-5). It occurs commonly in human tumors and is a major obstacle to successful chemotherapy. Consisting of two duplicated "halves" and a total length of around 1280 residues, it is a prominent member of the ABC transporter superfamily (6) and shows the typical ABC transporter domain arrangement consisting of two transmembrane domains (TMD) and two nucleotide-binding sites (NBS), in a linear sequence that can be represented as TMD1-NBS1-TMD2-NBS2. Current studies in many laboratories are aimed at understanding Pgp structure, function, normal physiology, and pharmacology.Our laboratory has studied the two nucleotide sites, and we have established that both are catalytic MgATP hydrolysis sites, which interact together closely (7-10). Earlier, we proposed (11) a catalytic mechanism for Pgp, in which the two NBS hydrolyze MgATP alternately, and hydrolysis is coupled to drug transport from an inner-facing, higher affinity, drug-binding site to an outer-facing, lower affinity site. Subsequent reports (12-16) have supported and extended this proposed mechanism. Further work (17-20) on the structure and location of the drug-binding sites has shown that certain transmembrane ␣-helices are involved in forming these sites, and work (21) with the closely related LmrA protein showed that transport is indeed from the inner lipid leaflet to the outer surface as proposed in Ref. 22. The mechanism of coupling of energy of ATP hydrolysis to transport of drugs is not well understood, however, at the present time. A preliminary structure of Pgp...